Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
ms [2017/04/18 09:41]
sflitman [Multiple Sclerosis]
ms [2018/12/22 14:19]
sflitman [Multiple Sclerosis]
Line 3: Line 3:
 Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans. ​ The most common form is Relapsing-Remitting,​ but there are also Primary Progressive,​ Secondary Progressive,​ and Progressive-Relapsing subtypes. ​ New trials are directed against the disease itself, hoping to slow progression,​ or against particular symptoms like spasticity (stiffness of muscles and limbs).  ​ Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans. ​ The most common form is Relapsing-Remitting,​ but there are also Primary Progressive,​ Secondary Progressive,​ and Progressive-Relapsing subtypes. ​ New trials are directed against the disease itself, hoping to slow progression,​ or against particular symptoms like spasticity (stiffness of muscles and limbs).  ​
  
-^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ​^ Duration ^ Open Label Extension ^ +^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Active ​^ Duration ^ Open Label Extension ^ 
-| Relapsing-Remitting Multiple Sclerosis |  B-cell depleting once-monthly subcutaneous injection vs. Aubagio |  III  |  Yes  |  50%  |  12 months ​ |  Yes  | +| Relapsing-Remitting Multiple Sclerosis |  Novel oral agent vs. Tecfidera ​ |  III  |  Yes  |  50%  |  ​11 weeks  ​|  ​96 weeks  |
-| Relapsing-Remitting Multiple Sclerosis |  Novel oral agent vs. Tecfidera ​ |  III  |  Yes  |  50%  |  ​12 months ​ ​|  ​Yes  |+
  
  
Print/export
QR Code
QR Code ms (generated for current page)